Uncategorized
Ocriplasmin approved for treatment of vitreomacular traction in European Union
The European Commission approved ocriplasmin to treat vitreomacular traction in the European Union, according to a press release from ThromboGenics.The approval, which includes cases in which vitreomacular traction is associated with a macular hole with a diameter of 400 µm or less, results in Alcon making a €45 million milestone payment to ThromboGenics. Another €45 million milestone payment will be made upon the first sale of Jetrea (ocriplasmin, ThromboGenics) in the EU, the release said.